Articles: function.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The ILLUMINATE study evaluated the superiority of once-daily QVA149 110/50μg, a dual bronchodilator combining the LABA indacaterol and LAMA glycopyrronium, compared to twice-daily LABA/ICS, salmeterol/fluticasone 50/500μg (SFC), in terms of efficacy, safety and tolerability in patients with moderate-to-severe COPD. This analysis reports the efficacy and safety of QVA149 versus SFC in the sub-group population using fixed-dose LABA/ICS prior to study enrollment. ⋯ Karen Mezzi: Employee: Novartis Employee John Pallante: Employee: Novartis Employee Vijay Alagappan: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Rare Disease Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amyloid Cardiomyopathy is characterized by bi-ventricular thickening due to amyloid deposition leading to diastolic dysfunction. ⋯ Cardiac amyloidosis should be considered in any adult with unexplained heart failure and an echocardiogram showing increased wall thickness with a nondilated left ventricular cavity, particularly when associated with low voltage on electrocardiogram.Reference #1: N/ADISCLOSURE: The following authors have nothing to disclose: Sameer Chadha, On Chen, Sunday Olatunde, Adnan Sadiq, Gerald Hollander, Jacob ShaniNo Product/Research Disclosure Information.
-
Critical Care Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: First described in 1950, cerebral salt wasting syndrome (CSW) is defined by development of extracellular volume depletion due to renal sodium transport abnormality in patients with intracranial disease and normal adrenal and thyroid function [1]. The entity has been controversial and its existence debatable. ⋯ This case illustrates the need for CSW recognition as a separate entity from SIADH. Failure to make this distinction in a patient with hyponatremia who has cranial conditions could lead to unbefitting and dangerous therapy with water restriction resulting in fatal outcomes.Reference #1: Peters JP, et al. A salt-wasting syndrome associated with cerebral disease. Trans Assc Am Phys. 1950, 63:57-64Reference #2: Schwartz WB, et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957 Oct 23(4):529-42DISCLOSURE: The following authors have nothing to disclose: Anita Rajagopal, John LuciaNo Product/Research Disclosure Information.
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pulse oximetry is nowadays a disseminated technology available almost over the corner. "Pocket" pulse oximeters are now widely available and knowing its precision and accuracy is of great importance in clinical practice. ⋯ The following authors have nothing to disclose: João Cordeiro da Costa, Ana Roque, Paula Faustino, Ricardo Lima, Filipa Viveiros, Miguel GuimarãesNo Product/Research Disclosure Information.